Financials Erasca, Inc.

Equities

ERAS

US29479A1088

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-04-26 EDT 5-day change 1st Jan Change
1.89 USD +0.53% Intraday chart for Erasca, Inc. +5.59% -11.27%

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 1,889 646.7 320.7 285.6 - -
Enterprise Value (EV) 1 1,475 211.1 320.7 102.8 48.3 -31.37
P/E ratio -8.42 x -2.17 x -2.57 x -2.12 x -1.93 x -1.81 x
Yield - - - - - -
Capitalization / Revenue - - - - 299 x -
EV / Revenue - - - - 50.6 x -
EV / EBITDA -11.9 x -0.86 x - -0.62 x -0.24 x 0.15 x
EV / FCF -15 x -1.76 x - -0.83 x -0.3 x 0.17 x
FCF Yield -6.68% -56.8% - -120% -329% 579%
Price to Book 2.26 x 1.28 x - 1.02 x 1.18 x 1.49 x
Nbr of stocks (in thousands) 121,250 150,054 150,572 151,122 - -
Reference price 2 15.58 4.310 2.130 1.890 1.890 1.890
Announcement Date 22-03-24 23-03-23 24-03-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 0.9541 -
EBITDA 1 - -124.1 -244.8 - -165.4 -199.3 -212.5
EBIT 1 - -124.9 -247.4 -141.5 -156 -180.7 -200.2
Operating Margin - - - - - -18,940.88% -
Earnings before Tax (EBT) 1 - -122.8 -242.8 -125 -136.1 -158.3 -185.6
Net income 1 -101.7 -122.8 -242.8 -125 -142.6 -168.5 -185.6
Net margin - - - - - -17,659.74% -
EPS 2 -4.836 -1.850 -1.990 -0.8300 -0.8933 -0.9785 -1.042
Free Cash Flow 1 - -98.48 -119.8 - -123.8 -159 -181.6
FCF margin - - - - - -16,663.87% -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 21-06-25 22-03-24 23-03-23 24-03-27 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - - - -
EBITDA -45.85 -30.73 -36.1 -35.37 -36.19 -137.1 - - - - - - - - -
EBIT 1 -46.04 -31.05 -36.5 -35.9 -36.96 -138.1 -37.02 -35.97 -34.66 -33.87 -35.31 -36.57 -38.02 -39.2 -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -46.07 -30.46 -36.46 -35.61 -35.49 -135.2 -33.2 -31.78 -30.36 -29.7 -30.5 -32.17 -33.73 -35.53 -
Net income 1 -46.07 -30.46 -36.46 -35.61 -35.49 -135.2 -33.2 -31.78 -30.36 -29.7 -30.92 -32.25 -34.2 -35.92 -
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.4600 -0.2600 -0.3100 -0.3000 -0.2900 -1.060 -0.2200 -0.2100 -0.2000 -0.2000 -0.1983 -0.2103 -0.2263 -0.2191 -0.2500
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 21-11-10 22-03-24 22-05-12 22-08-11 22-11-09 23-03-23 23-05-15 23-08-10 23-11-09 24-03-27 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 414 436 - 183 237 317
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -98.5 -120 - -124 -159 -182
ROE (net income / shareholders' equity) - -71.7% -55.9% - -42.8% -54.6% -67.5%
ROA (Net income/ Total Assets) - -39.2% -47.8% - - - -
Assets 1 - 313.1 508.2 - - - -
Book Value Per Share 2 - 6.890 3.380 - 1.860 1.600 1.270
Cash Flow per Share 2 - -1.200 -0.8500 - -0.9000 -1.160 -
Capex 1 - 18.9 16.6 - 2.43 2.78 3.41
Capex / Sales - - - - - 290.87% -
Announcement Date 21-06-25 22-03-24 23-03-23 24-03-27 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.89 USD
Average target price
7 USD
Spread / Average Target
+270.37%
Consensus
  1. Stock Market
  2. Equities
  3. ERAS Stock
  4. Financials Erasca, Inc.